Small molecule screen identifies pyrimethamine as an inhibitor of NRF2-driven esophageal hyperplasia-Reference-Cited by-同舟云学术

Small molecule screen identifies pyrimethamine as an inhibitor of NRF2-driven esophageal hyperplasia

Published:2023-11 Issue: Volume:67 Page:102901
ISSN:2213-2317
Container-title:Redox Biology
language:en
Short-container-title:Redox Biology

Author:

Paiboonrungruang Chorlada,Xiong Zhaohui,Lamson David,Li Yahui,Bowman Brittany,Chembo Julius,Huang Caizhi,Li Jianying,Livingston Eric W.,Frank Jon E.,Chen Vivian,Li Yong,Weissman Bernard,Yuan Hong,Williams Kevin P.,Ben Major M.,Chen Xiaoxin^ORCID

Publisher

Elsevier BV

Subject

Organic Chemistry,Biochemistry,Clinical Biochemistry

Reference51 articles.

1. Personalized and targeted therapy of esophageal squamous cell carcinoma: an update;Liu;Ann. N. Y. Acad. Sci.,2016

2. Personalized targeted therapy for esophageal squamous cell carcinoma;Kang;World J. Gastroenterol.,2015

3. Analysis Working Group: asan U, Agency BCC, Brigham, Women's H, Broad I, et al. Integrated genomic characterization of oesophageal carcinoma;Cancer Genome Atlas Research;Nature,2017

4. The KEAP1-NRF2 system and esophageal cancer;Hirose;Cancers,2022

5. NRF2 activation in cancer: from DNA to protein;Cloer;Cancer Res.,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Cancer Antioxidant Regulation System in Therapeutic Resistance;Antioxidants;2024-06-27

2. Differential squamous cell fates elicited by NRF2 gain of function versus KEAP1 loss of function;Cell Reports;2024-04

3. Pyrimethamine reduced tumour growth in pre-clinical cancer models: a systematic review to identify potential pre-clinical studies for subsequent human clinical trials;Biology Methods and Protocols;2024-01-01